We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Kit Simplifies Chromatin Immunoprecipitation-Based Assays

By LabMedica International staff writers
Posted on 26 Jul 2011
A new commercial assay based on chromatin immunoprecipitation (ChIP) is now available for purchase by biotech and genomics researchers.

Chromatin immunoprecipitation (ChIP) is a technique used to study the association of specific proteins, or their modified isoforms, with defined genomic regions. More...
In a ChIP assay, DNA-protein complexes are identified using matching antibodies and the resulting fractions treated to separate the DNA and protein components. Polymerase Chain Reaction (PCR), Real-time PCR, hybridization on microarrays, or direct sequencing is typically used to identify DNA fragments of defined sequence.

To make ChIP technology more user-friendly, Porvair Filtration Group (Ashland, VA, USA) has created the 24-assay Chromatrap Pro-A Chromatin ImmunoPrecipitation (ChIP) kit. The assay is based on Porvair’s novel Chromatrap technology, which offers a quicker, easier, and more efficient way of undertaking chromatin immunoprecipitation assays.

These kits employ Provair’s Chromatrap Pro-A spin columns, which contain discs of an inert, porous polymer to which protein A has been covalently attached. During an assay, the chromatin/antibody complex is retained by the disc. Flushing with three buffers and an elution step are all that is required to obtain the DNA fragments of interest.

Independent testing of the Chromatrap kit has demonstrated recovery of DNA up to 25 times higher than with traditional bead based procedures. In addition, they reported excellent DNA enrichment with signal-to-noise ratios typically two to three times better than competing procedures and top performance even with samples with as few as 15,000 cells per assay.

Related Links:

Porvair Filtration Group




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.